We are an early-stage biotech company dedicated to developing innovative treatments for high-impact autoimmune diseases like Rheumatoid Arthritis, Psoriathic arthritis, Psoriasis, Chron's disease.
After 10 years of pioneering in-house research, we have developed a breakthrough cell synthesis platform (MSYNC) and a candidate drug (MBN-1).
MSYNC and MBN-1 promise to be the foundation for a completely new generation of mAbs, whose pharmacological characteristics are expected to solve many of the drawbacks of currently available biological therapies.